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1raining on the Use of
ransendocardial Delivery of
iologics for Cardiac Regeneration
he delivery of biologics for cardiac regeneration is an emerging
spect of interventional cardiology, and we were interested to read
he recently published recommendations of the International
ociety for Cardiovascular Translational Research (ISCTR) Task
orce by Dib et al (1).
The ISCTR Task Force is to be commended for their efforts in
reating the published recommendations. Although we support
heir pre-clinical recommendations, we do not agree with the
ecommendations for clinical experience in the use of transendo-
ardial delivery of biologics. Animal lab experience, although
aluable, is not representative of the challenges involved in per-
orming clinical cases. In addition, we believe that the interven-
ionalist in training must become proficient in diagnostic mapping
nder the supervision of highly experienced operators before
ndertaking clinical injection procedures. Only after proficiency in
apping is demonstrated should the trainee continue to perform-
ng proctored clinical cases. In addition, we believe that trainees
hould successfully perform more proctored cases than recom-
ended by the ISCTR Task Force before obtaining certification.
Our recommendations for more proctored cases are based on
ur extensive experience with these procedures. We have been
erforming endocardial mapping for acute and chronic ischemia at
he Texas Heart Institute since 1998. Our experience in using
apping procedures in a cell therapy setting comprises multiple
arge animal studies and clinical trials, including the first U.S. Food
nd Drug Administration–approved trial in the U.S. in patients
ith chronic ischemia. Furthermore, we developed criteria and a
rotocol for the identification of viable myocardium and therapeu-ic injections with NOGA mapping. In 2000, we launched the
apping Excellence Program to train physicians throughout the
orld in endocardial mapping. As a training site for NOGA
ndocardial mapping and injection, we have developed a successful
raining program that includes a didactic overview, hands-on
raining in the animal laboratory, written and video materials,
esting, and certification. Upon completion of the program, phy-
icians are encouraged to send us their maps for review and
eedback before initiating their clinical injection programs.
The ISCTR’s suggested recommendations are an excellent
eginning. However, we believe that the suggested training guide-
ines are not stringent enough to ensure the safety of patients
ndergoing the NOGA-guided delivery of biologics. We suggest
urther dialogue and refining of the guidelines.
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